[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567210":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":30,"responsibleParty":33,"collaborators":30,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":30,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":30,"enrollmentInfo":45,"targetDuration":30,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":30,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":30},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Induction Therapy","EXPERIMENTAL","Patients were treated by G-Pola-ZLP as Induction Therapy",[13],"Drug: Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy","Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg\u002Fkg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg\u002Fm2 po qd d1-5) as induction therapy.",[9],[21],"G-Pola-ZLP",[23],{"name":24,"affiliation":5,"role":25},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+861066947194",null,"qlr2007@126.com",{"name":24,"role":28,"phone":30,"phoneExt":30,"email":30},{"type":25,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Liren Qian","Associate Chief Physician, Associate Professor","100567210","phase-2-g-pola-zlp-in-diffuse-large-b-cell-lymphoma-100567210",false,"NCT06665217","G-Pola-ZLP in Diffuse Large B-Cell Lymphoma","Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":46,"type":47},80,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.",[53],"Diffuse Large B-Cell Lymphoma","NOT_YET_RECRUITING","2025-08-13",{"date":57,"type":58},"2025-08-14","ACTUAL",{"date":60,"type":47},"2025-09-24",{"date":62,"type":47},"2030-01",{"name":5,"class":6}]